Quantum Genomics Société Anonyme (OTCMKTS:QNNTF) and Denali Therapeutics (NASDAQ:DNLI) Financial Contrast

Quantum Genomics Société Anonyme (OTCMKTS:QNNTFGet Rating) and Denali Therapeutics (NASDAQ:DNLIGet Rating) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

Insider and Institutional Ownership

69.2% of Denali Therapeutics shares are owned by institutional investors. 17.0% of Denali Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations for Quantum Genomics Société Anonyme and Denali Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Quantum Genomics Société Anonyme 0 0 0 0 N/A
Denali Therapeutics 0 0 8 0 3.00

Denali Therapeutics has a consensus target price of $91.14, suggesting a potential upside of 240.72%. Given Denali Therapeutics’ higher possible upside, analysts plainly believe Denali Therapeutics is more favorable than Quantum Genomics Société Anonyme.

Profitability

This table compares Quantum Genomics Société Anonyme and Denali Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Quantum Genomics Société Anonyme N/A N/A N/A
Denali Therapeutics -597.15% -27.99% -19.66%

Valuation and Earnings

This table compares Quantum Genomics Société Anonyme and Denali Therapeutics’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Quantum Genomics Société Anonyme N/A N/A N/A N/A N/A
Denali Therapeutics $48.66 million 67.53 -$290.58 million ($2.39) -11.19

Quantum Genomics Société Anonyme has higher earnings, but lower revenue than Denali Therapeutics.

Summary

Denali Therapeutics beats Quantum Genomics Société Anonyme on 5 of the 8 factors compared between the two stocks.

Quantum Genomics Société Anonyme Company Profile (Get Rating)

Quantum Genomics Société Anonyme, a biopharmaceutical company, develops drugs to treat cardiovascular diseases. It develops drugs based on brain aminopeptidase A inhibition (BAPAI) platform primarily to treat high blood pressure and heart failure. The company develops firibastat, a monotherapy drug that is in pivotal Phase III study for the treatment of hypertension; and in Phase IIb clinical trial for heart failure. It is also developing QGC011 that is in pre-clinical phase to treat hypertension with combination therapy; and QGC006 to optimize the treatment of hypertension with a monotherapy drug. The company was founded in 2005 and is based in Paris, France.

Denali Therapeutics Company Profile (Get Rating)

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Receive News & Ratings for Quantum Genomics Société Anonyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quantum Genomics Société Anonyme and related companies with MarketBeat.com's FREE daily email newsletter.